Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Metabolic Bone Diseases and New Drug Developments

  • Natesan, Vijayakumar (Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University) ;
  • Kim, Sung-Jin (Department of Pharmacology and Toxicology, Metabolic Diseases Research Laboratory, School of Dentistry, Kyung Hee University)
  • Received : 2022.01.16
  • Accepted : 2022.03.05
  • Published : 2022.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Metabolic bone diseases are serious health issues worldwide, since several million individuals over the age of 50 are at risk of bone damage and should be worried about their bone health. One in every two women and one in every four men will break a bone during their lifetime due to a metabolic bone disease. Early detection, raising bone health awareness, and maintaining a balanced healthy diet may reduce the risk of skeletal fractures caused by metabolic bone diseases. This review compiles information on the most common metabolic bone diseases (osteoporosis, primary hyperparathyroidism, osteomalacia, and fluorosis disease) seen in the global population, including their symptoms, mechanisms, and causes, as well as discussing their prevention and the development of new drugs for treatment. A large amount of research literature suggests that balanced nutrition and balanced periodic supplementation of calcium, phosphate, and vitamin D can improve re-absorption and the regrowth of bones, and inhibit the formation of skeletal fractures, except in the case of hereditary bone diseases. Meanwhile, new and improved drug formulations, such as raloxifene, teriparatide, sclerostin, denosumab, and abaloparatide, have been successfully developed and administered as treatments for metabolic bone diseases, while others (romososumab and odanacatib) are in various stages of clinical trials.

Keywords

References

  1. Abrahamsen, B., Pazianas, M., Eiken, P., Russell, R. G. and Eastell, R. (2012) Esophageal and gastric cancer incidence and mortality in alendronate users. J. Bone Miner. Res. 27, 679-686. https://doi.org/10.1002/jbmr.1481
  2. Ackerman, K. E. and Misra, M. (2011) Bone health and the female athlete triad in adolescent athletes. Phys. Sportsmed. 39, 131-141. https://doi.org/10.3810/psm.2011.02.1871
  3. Akuno, M. H., Nocella, G., Milia, E. P. and Gutierrez, L. (2019) Factors influencing the relationship between fluoride in drinking water and dental fluorosis: a ten-year systematic review and meta-analysis. J. Water Health 17, 845-862. https://doi.org/10.2166/wh.2019.300
  4. Al-Azem, H. and Khan, A. A. (2012) Hypoparathyroidism. Best Pract. Res. Clin. Endocrinol. Metab. 26, 517-522. https://doi.org/10.1016/j.beem.2012.01.004
  5. Albahri, A. S., Alwan, J. K., Taha, Z. K., Ismail, S. F., Hamid, R. A., Zaidan, A. A., Albahri, O. S., Zaidan, B. B., Alamoodi, A. H. and Alsalem, M. A. (2021) IoT-based telemedicine for disease prevention and health promotion: state-of-the-art. J. Netw. Comput. Appl. 173, 102873. https://doi.org/10.1016/j.jnca.2020.102873
  6. Anagnostis, P., Gkekas, N. K., Potoupnis, M., Kenanidis, E., Tsiridis, E. and Goulis, D. G. (2019) New therapeutic targets for osteoporosis. Maturitas 120, 1-6. https://doi.org/10.1016/j.maturitas.2018.11.010
  7. Anderson, H. C., Harmey, D., Camacho, N. P., Garimella, R., Sipe, J. B., Tague, S., Bi, X., Johnson, K., Terkeltaub, R. and Millan, J. L. (2005) Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice. Am. J. Pathol. 166, 1711-1720. https://doi.org/10.1016/S0002-9440(10)62481-9
  8. Arumugam, R., Natesan, V. and Mani, R. (2016) Effect of naringin on ammonium chloride-induced hyperammonemic rats: a dose-dependent study. J. Acute Med. 6, 55-60. https://doi.org/10.1016/j.jacme.2016.08.001
  9. Azizieh, F. Y. (2015) Incidence of hip fracture in Kuwait: a national registry-based study. Arch. Osteoporos. 10, 40. https://doi.org/10.1007/s11657-015-0248-x
  10. Barbosa, J. S., Braga, S. S. and Almeida Paz, F. A. (2020) Empowering the medicinal applications of bisphosphonates by unveiling their synthesis details. Molecules 25, 2821. https://doi.org/10.3390/molecules25122821
  11. Berg, S. H., Balogh, E. A., Ghamrawi, R. I. and Feldman, S. R. (2021) A review of secukinumab in psoriasis treatment. Immunotherapy 13, 201-216. https://doi.org/10.2217/imt-2020-0195
  12. Bergwitz, C. and Juppner, H. (2010) Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu. Rev. Med. 61, 91-104. https://doi.org/10.1146/annurev.med.051308.111339
  13. Blau, J. E. and Simonds, W. F. (2021) Familial hyperparathyroidism. Front. Endocrinol. 12, 623667. https://doi.org/10.3389/fendo.2021.623667
  14. Bonakdarpour, A. (2009) Systematic approach to metabolic diseases of bone. In Diagnostic Imaging of Musculoskeletal Diseases, pp. 15-59. Springer.
  15. Brini, M., Ottolini, D., Cali, T. and Carafoli, E. (2013) Calcium in health and disease. Met. Ions Life Sci. 13, 81-137. https://doi.org/10.1007/978-94-007-7500-8_4
  16. Carbone, L. D., Gonzalez, B., Miskevics, S., Ray, C., Etingen, B., Guihan, M., Craven, B. C., George, V. and Weaver, F. M. (2020) Association of bisphosphonate therapy with incident of lower extremity fractures in persons with spinal cord injuries or disorders. Arch. Phys. Med. Rehabil. 101, 633-641. https://doi.org/10.1016/j.apmr.2019.12.010
  17. Cashman, K. D., Ritz, C., Adebayo, F. A., Dowling, K. G., Itkonen, S. T., Ohman, T., Skaffari, E., Saarnio, E. M., Kiely, M. and Lamberg-Allardt, C. (2019) Differences in the dietary requirement for vitamin D among Caucasian and East African women at Northern latitude. Eur. J. Nutr. 58, 2281-2291. https://doi.org/10.1007/s00394-018-1775-1
  18. Cavalier, E., Bergmann, P., Bruyere, O., Delanaye, P., Durnez, A., Devogelaer, J. P., Ferrari, S. L., Gielen, E., Goemaere, S., Kaufman, J. M., Toukap, A. N., Reginster, J. Y., Rousseau, A. F., Rozenberg, S., Scheen, A. J. and Body, J. J. (2016) The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club. Osteoporos. Int. 27, 2181-2195. https://doi.org/10.1007/s00198-016-3561-3
  19. Chinoy, A., Mughal, M. Z. and Padidela, R. (2019) Metabolic bone disease of prematurity: causes, recognition, prevention, treatment and long-term consequences. Arch. Dis. Child. Fetal Neonatal Ed. 104, F560-F566. https://doi.org/10.1136/archdischild-2018-316330
  20. Ciobanu, G., De Angelis, F., Slabari, E. and Pompa, G. (2021) Bone mineralization and immediate function of six dental implants in patients with Klinefelter syndrome. Clin. Case Rep. 9, e03142.
  21. Cooper, C., Westlake, S., Harvey, N., Javaid, K., Dennison, E. and Hanson, M. (2006) Review: developmental origins of osteoporotic fracture. Osteoporos. Int. 17, 337-347. https://doi.org/10.1007/s00198-005-2039-5
  22. Curtis, E. M., Harvey, N. C. and Cooper, C. (2018) The burden of osteoporosis. In Osteoporosis: a Lifecourse Epidemiology Approach to Skeletal Health, pp. 1-20. CRC Press.
  23. Curtis, E. M., van der Velde, R., Moon, R. J., van den Bergh, J. P., Geusens, P., de Vries, F., van Staa, T. P., Cooper, C. and Harvey, N. C. (2016) Epidemiology of fractures in the United Kingdom 1988-2012: variation with age, sex, geography, ethnicity, and socioeconomic status. Bone 87, 19-26. https://doi.org/10.1016/j.bone.2016.03.006
  24. Cusano, N. E., Rubin, M. R., Irani, D., Sliney, J. and Bilezikian, J. P. (2013) Use of parathyroid hormone in hypoparathyroidism. J. Endocrinol. Invest. 36, 1121-1127. https://doi.org/10.1007/BF03346763
  25. Drake, M. T., Clarke, B. L. and Lewiecki, E. M. (2015) The pathophysiology and treatment of osteoporosis. Clin. Ther. 37, 1837-1850. https://doi.org/10.1016/j.clinthera.2015.06.006
  26. Dubey, A. K., Handu, S. S., Dubey, S., Sharma, P., Sharma, K. K. and Ahmed, Q. M. (2011) Belimumab: first targeted biological treatment for systemic lupus erythematosus. J. Pharmacol. Pharmacother. 2, 317-319. https://doi.org/10.4103/0976-500X.85930
  27. Ethgen, O., Hiligsmann, M., Burlet, N. and Reginster, J. Y. (2016) Costeffectiveness of personalized supplementation with vitamin D-rich dairy products in the prevention of osteoporotic fractures. Osteoporos. Int. 27, 301-308. https://doi.org/10.1007/s00198-015-3319-3
  28. Fabre, S., Funck-Brentano, T. and Cohen-Solal, M. (2020) Anti-sclerostin antibodies in osteoporosis and other bone diseases. J. Clin. Med. 9, 3439. https://doi.org/10.3390/jcm9113439
  29. Gennari, C. (2001) Calcium and vitamin D nutrition and bone disease of the elderly. Public Health Nutr. 4, 547-559. https://doi.org/10.1079/PHN2001140
  30. Gopinath, P. and Mihai, R. (2011) Hyperparathyroidism. Surgery 29, 451-458. https://doi.org/10.1016/j.mpsur.2011.06.015
  31. Guo, Y., Lu, N. and Bai, A. (2013) Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update. Biomed. Res. Int. 2013, 581631.
  32. Haboubi, N. and Jones, S. (2007) Coeliac disease. From A-Z. Expert Opin. Ther. Pat. 17, 799-817. https://doi.org/10.1517/13543776.17.7.799
  33. Herford, A. S. (2017) The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in maxillofacial trauma. Chin. J. Traumatol. 20, 1-3. https://doi.org/10.1016/j.cjtee.2016.05.004
  34. Hernlund, E., Svedbom, A., Ivergard, M., Compston, J., Cooper, C., Stenmark, J., McCloskey, E. V., Jonsson, B. and Kanis, J. A. (2013) Osteoporosis in the European Union: medical management, epidemiology, and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch. Osteoporos. 8, 136. https://doi.org/10.1007/s11657-013-0136-1
  35. Hossein-nezhad, A. and Holick, M. F. (2013) Vitamin D for health: a global perspective. Mayo Clin. Proc. 88, 720-755. https://doi.org/10.1016/j.mayocp.2013.05.011
  36. Izumiyama, T., Yu, M. and Eiji, I. (2020) Tocilizumab was effective in repairing the large geode in a patient with rheumatoid arthritis. Case Rep. Rheumatol. 2020, 8899391.
  37. Jiang, M., Liu, R., Liu, L., Kot, A., Liu, X., Xiao, W., Jia, J., Li, Y., Lam, K. and Yao, W. (2020) Identification of osteogenic progenitor celltargeted peptides that augment bone formation. Nat. Commun. 11, 4278-4292. https://doi.org/10.1038/s41467-020-17417-9
  38. Juhlin, C. C. and Erickson, L. A. (2021) Genomics and epigenomics in parathyroid neoplasia: from bench to surgical pathology practice. Endocr. Pathol. 32, 17-34. https://doi.org/10.1007/s12022-020-09656-9
  39. Kanis, J. A., Cooper, C., Rizzoli, R. and Reginster, J. Y. (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 30, 3-44. https://doi.org/10.1007/s00198-018-4704-5
  40. Kapic, E., Becic, F. and Kusturica, J. (2004) Basiliximab, mechanism of action and pharmacological properties. Med. Arh. 58, 373-376.
  41. Kaveh, S., Hosseinifard, H., Ghadimi, N., Vojdanian, M. and Aryankhesal, A. (2020) Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis. Clin. Rheumatol. 39, 3261-3276. https://doi.org/10.1007/s10067-020-04948-1
  42. Kim, M. E., Seon, J. K., Kang, J. Y., Yoon, T. R., Lee, J. S. and Kim, H. K. (2021) Bone-forming peptide-4 induces osteogenic differentiation and VEGF expression on multipotent bone marrow stromal cells. Front. Bioeng. Biotechnol. 9, 734483. https://doi.org/10.3389/fbioe.2021.734483
  43. Kim, M. K., Yun, K. J., Kim, M. H., Lim, D. J., Kwon, H. S., Song, K. H., Kang, M. I. and Baek, K. H. (2015) The effects of thyrotropinsuppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Bone 71, 101-105. https://doi.org/10.1016/j.bone.2014.10.009
  44. Klemmer, V. A., Khera, N., Siegenthaler, B. M., Bhattacharya, I., Weber, F. E. and Ghayor, C. (2021) Effect of N-Vinyl-2-Pyrrolidone (NVP), a bromodomain-binding small chemical, on osteoblast and osteoclast differentiation and its potential application for bone regeneration. Int. J. Mol. Sci. 22, 11052. https://doi.org/10.3390/ijms222011052
  45. Knechtle, B., Jastrzebski, Z., Hill, L. and Nikolaidis, P. T. (2021) Vitamin D and stress fractures in sport: preventive and therapeutic measures-a narrative review. Medicina 57, 223. https://doi.org/10.3390/medicina57030223
  46. Komoroski, M., Azad, N. and Camacho, P. (2014) Disorders of bone and bone mineral metabolism. Handb. Clin. Neurol. 120, 865-887. https://doi.org/10.1016/B978-0-7020-4087-0.00058-9
  47. Konda, P. Y., Poondla, V., Jaiswal, K. K., Dasari, S., Uyyala, R., Surtineni, V. P. and Natesan, V. (2020) Pathophysiology of high fat diet induced obesity: impact of probiotic banana juice on obesity associated complications and hepatosteatosis. Sci. Rep. 10, 16894. https://doi.org/10.1038/s41598-020-73670-4
  48. Laroche, M., Couture, G., Ruyssen-Witrand, A., Constantin, A. and Degboe, Y. (2020) Effect of risedronate on bone loss at discontinuation of denosumab. Bone Rep. 13, 100290. https://doi.org/10.1016/j.bonr.2020.100290
  49. Leib, E. S., Saag, K. G., Adachi, J. D., Geusens, P. P., Binkley, N., McCloskey, E. V. and Hans, D. B.; FRAX(®) Position Development Conference Members (2011) Official Positions for FRAX(®) clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX(®) of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). J. Clin. Densitom. 14, 212-219. https://doi.org/10.1016/j.jocd.2011.05.014
  50. Levine, M. A. (2012) Assessing bone health in children and adolescents. Indian J. Endocrinol. Metab. 16, S205-S212. https://doi.org/10.4103/2230-8210.104040
  51. Lim, S. Y. and Bolster, M. B. (2017) Profile of romosozumab and its potential in the management of osteoporosis. Drug Des. Devel. Ther. 11, 1221-1231. https://doi.org/10.2147/DDDT.S127568
  52. Lombardi, G., Ziemann, E., Banfi, G. and Corbetta, S. (2020) Physical activity-dependent regulation of parathyroid hormone and calciumphosphorous metabolism. Int. J. Mol. Sci. 21, 5388. https://doi.org/10.3390/ijms21155388
  53. Lopes, D., Martins-Cruz, C., Oliveira, M. B. and Mano, J. F. (2018) Bone physiology as inspiration for tissue regenerative therapies. Biomaterials 185, 240-275. https://doi.org/10.1016/j.biomaterials.2018.09.028
  54. Lu, J., Wang, M., Wang, Z., Fu, Z., Lu, A. and Zhang, G. (2018) Advances in the discovery of cathepsin K inhibitors on bone resorption. J. Enzyme Inhib. Med. Chem. 33, 890-904. https://doi.org/10.1080/14756366.2018.1465417
  55. Marsh, D., Akesson, K., Beaton, D. E., Bogoch, E. R., Boonen, S., Brandi, M. L., McLellan, A. R., Mitchell, P. J., Sale, J. E. and Wahl, D. A. (2011) Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos. Int. 22, 2051-2065. https://doi.org/10.1007/s00198-011-1642-x
  56. McDonald, J., Wooderchak-Donahue, W., VanSant Webb, C., White-head, K., Stevenson, D. A. and Bayrak-Toydemir, P. (2015) Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era. Front. Genet. 6, 1. https://doi.org/10.3389/fgene.2015.00001
  57. McKeage, K. and Perry, C. M. (2002) Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62, 209-243. https://doi.org/10.2165/00003495-200262010-00008
  58. Minich, D. M. (2019) A review of the science of colorful, plant-based food and practical strategies for "eating the rainbow". J. Nutr. Metab. 2019, 2125070. https://doi.org/10.1155/2019/2125070
  59. Moen, M. D. and Keam, S. J. (2011) Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging 28, 63-82. https://doi.org/10.2165/11203300-000000000-00000
  60. Morgan, B., Mant, M., de la Cova, C. and Brickley, M. B. (2020) Osteoporosis, osteomalacia, and hip fracture: a case study from the Terry collection. Int. J. Paleopathol. 30, 17-21. https://doi.org/10.1016/j.ijpp.2020.03.004
  61. Natesan, V. and Kim, S. J. (2021a) Diabetic nephropathy-a review of risk factors, progression, mechanism, and dietary management. Biomol. Ther. (Seoul) 29, 365-372. https://doi.org/10.4062/biomolther.2020.204
  62. Natesan, V. and Kim, S. J. (2021b) Lipid metabolism, disorders and therapeutic drugs - review. Biomol. Ther. (Seoul) 29, 596-604. https://doi.org/10.4062/biomolther.2021.122
  63. Nilsson, I. L. (2019) Primary hyperparathyroidism: should surgery be performed on all patients? Current evidence and residual uncertainties. J. Intern. Med. 285, 149-164. https://doi.org/10.1111/joim.12840
  64. Ott, S. M. and Elder, G. J. (2021) Osteoporosis associated with chronic kidney disease. In Marcus and Feldman's Osteoporosis, pp. 1325-1380. Academic Press.
  65. Pelechas, E., Voulgari, P. V. and Drosos, A. A. (2019) Golimumab for rheumatoid arthritis. J. Clin. Med. 8, 387. https://doi.org/10.3390/jcm8030387
  66. Peraza-Delgado, A., Sanchez-Gomez, M. B., Gomez-Salgado, J., Romero-Martin, M., Novo-Munoz, M. and Duarte-Climents, G. (2020) Non-pharmacological interventions towards preventing the triad osteoporosis-falls risk-hip fracture, in population older than 65. scoping review. J. Clin. Med. 9, 2329. https://doi.org/10.3390/jcm9082329
  67. Petrone, P., Fabio, M., Guarino, B., Giustino, S. and Gombos, F. (2013) Ancient and recent evidence of endemic fluorosis in the Naples area. J. Geochem. Explor. 131, 14-27. https://doi.org/10.1016/j.gexplo.2012.11.012
  68. Pludowski, P., Holick, M. F., Grant, W. B., Konstantynowicz, J., Mascarenhas, M. R., Haq, A., Povoroznyuk, V., Balatska, N., Barbosa, A. P., Karonova, T., Rudenka, E., Misiorowski, W., Zakharova, I., Rudenka, A., Lukaszkiewicz, J., Marcinowska-Suchowierska, E., Laszcz, N., Abramowicz, P., Bhattoa, H. P. and Wimalawansa, S. J. (2018) Vitamin D supplementation guidelines. J. Steroid Biochem. Mol. Biol. 175, 125-135. https://doi.org/10.1016/j.jsbmb.2017.01.021
  69. Polyzos, S. A., Cundy, T. and Mantzoros, C. S. (2018) Juvenile Paget disease. Metab. Clin. Exp. 80, 15-26. https://doi.org/10.1016/j.metabol.2017.10.007
  70. Provinciali, N., Suen, C., Dunn, B. K. and DeCensi, A. (2016) Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women. Expert Rev. Clin. Pharmacol. 9, 1263-1272. https://doi.org/10.1080/17512433.2016.1231575
  71. Ramakrishnan, A. and Vijayakumar, N. (2017) Urea cycle pathway targeted therapeutic action of naringin against ammonium chloride induced hyperammonemic rats. Biomed. Pharmacother. 94, 1028-1037. https://doi.org/10.1016/j.biopha.2017.08.028
  72. Ramya, A., Vijayakumar, N. and Renuka, M. (2015) Antiarthritic effect of aqueous extract of lawsonia inermis. L-an in vitro study. Int. J. Modn. Res. Revs. 3, 744-747.
  73. Rasool, A., Farooqi, A., Xiao, T., Ali, W., Noor, S., Abiola, O., Ali, S. and Nasim, W. (2018) A review of global outlook on fluoride contamination in groundwater with prominence on the Pakistan current situation. Environ. Geochem. Health 40, 1265-1281. https://doi.org/10.1007/s10653-017-0054-z
  74. Reyes, C., Hitz, M., Prieto-Alhambra, D. and Abrahamsen, B. (2016) Risks and benefits of bisphosphonate therapies. J. Cell. Biochem. 117, 20-28. https://doi.org/10.1002/jcb.25266
  75. Rivadeneira, F. and Makitie, O. (2016) Osteoporosis and bone mass disorders: from gene pathways to treatments. Trends Endocrinol. Metab. 27, 262-281. https://doi.org/10.1016/j.tem.2016.03.006
  76. Sahu, P., Kisku, G., Singh, P., Kumar, V., Kumar, P. and Shukla, N. (2018) Multivariate statistical interpretation on seasonal variations of fluoride-contaminated groundwater quality of Lalganj Tehsil, Raebareli District (UP), India. Environ. Earth Sci. 77, 484. https://doi.org/10.1007/s12665-018-7658-1
  77. Samaee, H., Mohsenzadegan, M., Ala, S., Maroufi, S. S. and Moradimajd, P. (2020) Tocilizumab for treatment patients with COVID-19: recommended medication for novel disease. Int. Immunopharmacol. 89, 107018. https://doi.org/10.1016/j.intimp.2020.107018
  78. Sanghi, D., Saini, P., Mishra, P. and Sharma, M. (2021) Outbreaks in India: impact on socio-economy and health. J. Commun. Dis. 53, 35-44.
  79. Scollon, S., Anglin, A. K., Thomas, M., Turner, J. T. and Wolfe Schneider, K. (2017) A comprehensive review of pediatric tumors and associated cancer predisposition syndromes. J. Genet. Couns. 26, 387-434. https://doi.org/10.1007/s10897-017-0077-8
  80. Sellami, M., Riahi, H., Maatallah, K., Ferjani, H., Bouaziz, M. C. and Ladeb, M. F. (2020) Skeletal fluorosis: don't miss the diagnosis! Skelet. Radiol. 49, 345-357.
  81. Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., Ebeling, P. R., Einhorn, T. A., Genant, H. K., Geusens, P., Klaushofer, K., Lane, J. M., McKiernan, F., McKinney, R., Ng, A., Nieves, J., O'Keefe, R., Papapoulos, S., Howe, T. S., van der Meulen, M. C., Weinstein, R. S. and Whyte, M. P. (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 29, 1-23. https://doi.org/10.1002/jbmr.1998
  82. Skjodt, M. K., Frost, M. and Abrahamsen, B. (2019) Side effects of drugs for osteoporosis and metastatic bone disease. Br. J. Clin. Pharmacol. 85, 1063-1071. https://doi.org/10.1111/bcp.13759
  83. Skowronska-Jozwiak, E. and Lorenc, R. S. (2006) Metabolic bone disease in children: etiology and treatment options. Treat. Endocrinol. 5, 297-318. https://doi.org/10.2165/00024677-200605050-00004
  84. Soyka, L. A., Wesley, P. and Klibanski, F. A. (2000) Hormonal determinants and disorders of peak bone mass in children. J. Clin. Endocrinol. Metab. 85, 3951-3963. https://doi.org/10.1210/jcem.85.11.6994
  85. Sozen, T., Ozisik, L. and Basaran, N. C. (2017) An overview and management of osteoporosis. Eur. J. Rheumatol. 4, 46-56. https://doi.org/10.5152/eurjrheum.2016.048
  86. Srivastava, S. and Flora, S. (2020) Fluoride in drinking water and skeletal fluorosis: a review of the global impact. Curr. Environ. Health Rep. 7, 140-146. https://doi.org/10.1007/s40572-020-00270-9
  87. Stoffer, K., Bistas, K. G., Reddy, V. and Shah, S. (2022) Abciximab. StatPearls.
  88. Swanson, C. M., Shea, S. A., Stone, K. L., Cauley, J. A., Rosen, C. J., Redline, S., Karsenty, G. and Orwoll, E. S. (2015) Obstructive sleep apnea and metabolic bone disease: insights into the relationship between bone and sleep. J. Bone Miner. Res. 30, 199-211. https://doi.org/10.1002/jbmr.2446
  89. Swanson, W. B., Zhang, Z., Xiu, K., Gong, T., Eberle, M., Wang, Z. and Ma, P. X. (2020) Scaffolds with controlled release of pro-mineralization exosomes to promote craniofacial bone healing without cell transplantation. Acta Biomater. 118, 215-232. https://doi.org/10.1016/j.actbio.2020.09.052
  90. Tarantino, U., Baldi, J., Celi, M., Rao, C., Liuni, F. M., Iundusi, R. and Gasbarra, E. (2013) Osteoporosis and sarcopenia: the connections. Aging Clin. Exp. Res. 25, S93-S95.
  91. Tarantino, U., Cariati, I., Greggi, C., Gasbarra, E., Belluati, A., Ciolli, L., Maccauro, G., Momoli, A., Ripanti, S., Falez, F. and Brandi, M. L. (2021) Skeletal system biology and smoke damage: from basic science to medical clinic. Int. J. Mol. Sci. 22, 6629. https://doi.org/10.3390/ijms22126629
  92. Tay, D., Cremers, S. and Bilezikian, J. P. (2018) Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology. Br. J. Clin. Pharmacol. 84, 252-267. https://doi.org/10.1111/bcp.13455
  93. Thanh, N. C., Devi Rajeswari, V., Narayanan, M., Kandasamy, S., Chinnathambi, A., Ali Alharbi, S., Van Le, Q. and Kathirvel, B. (2021) Evaluation of probiotic susceptibility of virulent Aeromonas sp. by a study on gut histology of Cyprinus carpio. Process Biochem. 111, 154-159. https://doi.org/10.1016/j.procbio.2021.10.023
  94. Tu, K. N., Lie, J. D., Wan, C., Cameron, M., Austel, A. G., Nguyen, J. K., Van, K. and Hyun, D. (2018) Osteoporosis: a review of treatment options. P T 43, 92-104.
  95. Tuli, G., Buganza, R., Tessaris, D., Einaudi, S., Matarazzo, P. and de Sanctis, L. (2020) Teriparatide (rhPTH 1-34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism. Endocrine 67, 457-465. https://doi.org/10.1007/s12020-019-02128-z
  96. Uday, S. and Hogler, W. (2017) Nutritional rickets and osteomalacia in the twenty-first century: revised concepts, public health, and prevention strategies. Curr. Osteoporos. Rep. 15, 293-302. https://doi.org/10.1007/s11914-017-0383-y
  97. Van Horn, L., Carson, J. A., Appel, L. J., Burke, L. E., Economos, C., Karmally, W., Lancaster, K., Lichtenstein, A. H., Johnson, R. K., Thomas, R. J., Vos, M., Wylie-Rosett, J. and Kris-Etherton, P.; American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Stroke Council (2016) Recommended dietary pattern to achieve adherence to the American Heart Association/American College of Cardiology (AHA/ACC) guidelines: a scientific statement from the American Heart Association. Circulation 134, e505-e529. https://doi.org/10.1161/CIR.0000000000000462
  98. Vijayakumar, N. and Subramanian, P. (2010a) Neuroprotective effect of Semecarpus anacardium against hyperammonemia in rats. J. Pharm. Res. 3, 1564-8.
  99. Vijayakumar, N. and Subramanian, P. (2010b) Protective effect of Semecarpus anacardium nut extract against hyperammonemia in rats. J. Herb. Med. Toxicol. 4, 77-82.
  100. Vondracek, S. F. and Linnebur, S. A. (2009) Diagnosis and management of osteoporosis in the older senior. Clin. Interv. Aging 4, 121-136. https://doi.org/10.2147/CIA.S4965
  101. Wei, C. H. and Harari, A. (2012) Parathyroid carcinoma: update and guidelines for management. Curr. Treat. Options Oncol. 13, 11-23. https://doi.org/10.1007/s11864-011-0171-3
  102. Xue, S., Wang, Y., Han, X., Yi, H., Jiang, W., Si, S., Guo, H. and Li, Z. (2019) Novel cathepsin K inhibitors block osteoclasts in vitro and increase spinal bone density in zebrafish. RSC Adv. 9, 8600-8607. https://doi.org/10.1039/c8ra10338k
  103. Yang, G., Nowsheen, S., Aziz, K. and Georgakilas, A. G. (2013) Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs. Pharmacol. Ther. 139, 392-404. https://doi.org/10.1016/j.pharmthera.2013.05.005
  104. Yoshimura, N., Muraki, S., Oka, H., Iidaka, T., Kodama, R., Kawaguchi, H., Nakamura, K., Tanaka, S. and Akune, T. (2017) Is osteoporosis a predictor for future sarcopenia or vice versa? Four-year observations between the second and third ROAD study surveys. Osteoporos. Int. 28, 189-199. https://doi.org/10.1007/s00198-016-3823-0
  105. Zheng, Z., Geng, J., Jiang, Y., Zhang, M., Yang, R., Ge, G. and Zhang, X. (2021) Kidney diseases. In Clinical Molecular Diagnostics (S. Pan and J. Tang, Eds.), pp. 553-582. Springer, Singapore.